GREENFIELD, Ind., Aug. 5,
2015 /PRNewswire/ -- Today Elanco Animal Health, a subsidiary of
Eli Lilly & Co. (NYSE: LLY), announced the launch of OSURNIA, a
treatment for canine otitis externa*. An estimated one in 5 dogs
will experience the discomfort of otitis externa1 – an
inflammation of the ear canal that is often accompanied by ear
pain, itchy ears, a strong odor and muffled hearing.2
Otitis externa is the second most common canine veterinary
diagnosis in the U.S.3 and owner compliance is the
biggest issue veterinarians face when treating these affected
dogs.1
OSURNIA has the potential to help improve compliance in treating
canine otitis externa, due to its convenient gel formulation and
administration schedule that calls for two doses, one week apart.
Canine otitis externa has a recurrence rate of 50 to 60 percent,
and pet owners can become frustrated as they see their dog
experiencing repeated pain and discomfort.1
"Pet owner compliance is one of the biggest challenges
veterinarians face when treating otitis externa in dogs," says Dr.
Wayne Rosenkrantz, DVM, ACVD, from
the Animal Dermatology Clinic, Tustin,
CA. "With OSURNIA, the innovation of an effective treatment
administered in just two doses is much more convenient for pet
owners and will increase the likelihood that they will complete the
entire treatment program."
OSURNIA is administered in a pre-measured, easy-to-use
single-dose tube with a flexible, soft tip that is meant to be
gentle on a dog's ears. Osurnia is an adaptable gel4,
not a liquid or ointment. The gel formulation squeezes out of the
tube and spreads easily with gentle massage4. The
two-dose treatment regimen is administered seven days apart, which
can help increase compliance through convenience.1
Veterinarians interested in OSURNIA should talk to their Elanco
sales representative or call 1-877-352-6261 for information.
*OSURNIA is indicated for the treatment of otitis externa in
dogs associated with susceptible strains of bacteria
(Staphylococcus pseudintermedius) and yeast (Malassezia
pachydermatis).
IMPORTANT SAFETY INFORMATION
OSURNIA (florfenicol/terbinafine/betamethasone acetate) is for
otic use only under veterinary supervision. Do not use on dogs with
known tympanic perforation or a hypersensitivity to florfenicol,
terbinafine or corticosteroids. Adverse reactions observed during
clinical trials include vomiting, increased liver enzymes and
transient loss of hearing. Please see attached product insert for
full prescribing information.
ABOUT ELANCO PRODUCTS
Osurnia joins Elanco's broad portfolio of products including
Atopica® (Cyclosporine capsules, USP) MODIFIED,
Atopica® for Cats (cyclosporine oral solution, USP)
MODIFIED, Fresvio® and Surolan® (miconazole
nitrate, polymyxin B sulfate, prednisolone acetate).
ABOUT ELANCO
Elanco provides comprehensive products and knowledge services to
improve animal health and food-animal production in more than 70
countries around the world. We value innovation, both in scientific
research and daily operations, and strive to cultivate a
collaborative work environment for nearly 7,000 employees
worldwide. Together with our customers, we are committed to raising
awareness about global food security, and celebrating and
supporting the human-animal bond. Founded in 1954, Elanco is a
division of Eli Lilly and Company. Our worldwide headquarters and
research facilities are located in Greenfield, Indiana. Visit us at
Elanco.com.
SOURCES
1. Kadence: Gauging Interest in a New
OE Treatment, Quantitative Results, September 2013
2. AVCS Otitis Media
https://www.acvs.org/small-animal/otitis-externa (accessed
7/1/15)
3. VPI's press
release: http://press.petinsurance.com/pressroom/448.aspx
(4/14/15)
4. Elanco data on file
PDF -
http://origin-qps.onstreammedia.com/origin/multivu_archive/ENR/255193-Elanco-Animal-Health-Osurnia-PDF.pdf
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/elanco-animal-health-launches-osurnia-florfenicolterbinafinebetamethasone-acetate-a-new-two-dose-otitis-externa-treatment-for-dogs-300123720.html
SOURCE Elanco Animal Health